Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by DaveAuon Jan 31, 2008 10:50am
466 Views
Post# 14296160

Very encouraged

Very encouragedBelow text in italics was posted by carmyk1 on the V2 board. The answer to his question is Yes. So the third patient met the criteria and we only need 5 more. Moving to a registration trial would be an absolutely huge event for this company. I can't over emphasize the "huge". Its only one patient and we won't know about others for a while and I know we've been disappointed before but the market cap of the company is quite low and the level of interest is low so it looks to me like a good place to add for speculative accounts. David Miller at BTM reported that the protocol also states that if there is a response rate of 15% or better, ONC will be able to expand the trial to registration status. So one question is whether SD for six months counts as a response for this aspect of the protocol. If so, then one more good outcome from the five remaining patients and we are on track.
Bullboard Posts